Verici Logo

Investor Update

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that Sara Barrington, CEO, will provide a live presentation relating to positive data from the Tuteva™ clinical validation study via the Investor Meet Company platform on 17 June 2022 at 4:30pm BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet VERICI DX PLC via: https://www.investormeetcompany.com/verici-dx-plc/register-investor

Investors who already follow VERICI DX PLC on the Investor Meet Company platform will automatically be invited.Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that an interview with Chief Executive, Sara Barrington, has been published this morning highlighting the positive performance data for Tuteva™, the Company’s post-transplant blood test focused on acute rejection. The interview can be viewed here: https://www.voxmarkets.co.uk/articles/verici-dx-interview-with-ceo-sara-barrington-c2bbfd2/

In the interview, Sara highlights that the data from its blinded, international, multi-centre validation study shows the superior clinical performance of Tuteva™ compared to existing diagnostics “by multiple times” and that the data received a very positive response at the American Transplant Congress (“ATC”) earlier this month.

The interview follows on from the news announced yesterday of further data demonstrating the effectiveness of the test in providing clinicians with actionable information to better inform the medical management of kidney transplant patients. Yesterday’s announcement can be seen here: https://vericidx.com/tuteva-clinical-validation-study/

The positive performance data establishes a new industry standard in detection of acute kidney transplant rejection and paves way for US commercial launch in 2022.

The headline result from the study was originally announced on 12 May, which can be seen here: https://vericidx.com/positive-results-for-tuteva/

 


 

Enquiries:

Verici Dx
Sara Barrington, CEO
Julian Baines, Chairman

www.vericidx.com
Via Walbrook PR

N+1 Singer (Nominated Adviser & Broker)
Aubrey Powell / Kailey Aliyar / Tom Salvesen
Tel: 020 7496 3000
Walbrook PR Limited
Paul McManus / Sam Allen

Tel: 020 7933 8780 or vericidx@walbrookpr.com
Mob: 07980 541 893 /
07502 558 258

 


 

About Verici Dx plc

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

crossmenu